Effects of conflicting prescription drug information from direct-to-consumer advertising and drug injury advertising on patients’ beliefs and medication adherence

2021 ◽  
Author(s):  
Heewon Im ◽  
Jisu Huh
Keyword(s):  
Medication Adherence ◽  
Prescription Drug ◽  
Drug Information ◽  
Direct To Consumer ◽  
Direct To Consumer Advertising

scholarly journals Effects of comparative claims in prescription drug direct-to-consumer advertising on consumer perceptions and recall

2014 ◽  
Vol 120 ◽  
pp. 1-11 ◽  
Author(s):  
Amie C. O'Donoghue ◽  
Pamela A. Williams ◽  
Helen W. Sullivan ◽  
Vanessa Boudewyns ◽  
Claudia Squire ◽  
...  
Keyword(s):  
Prescription Drug ◽  
Consumer Perceptions ◽  
Direct To Consumer ◽  
Direct To Consumer Advertising

scholarly journals Demand Effects of Recent Changes in Prescription Drug Promotion

2003 ◽  
Vol 6 (1) ◽  
Author(s):  
Meredith B. Rosenthal ◽  
Ernst R. Berndt ◽  
Julie M. Donohue ◽  
Arnold M. Epstein ◽  
Richard G. Frank
Keyword(s):  
Prescription Drug ◽  
Drug Market ◽  
Drug Spending ◽  
Direct To Consumer ◽  
On Demand ◽  
Therapeutic Class ◽  
Drug Promotion ◽  
Prescription Drug Spending ◽  
Direct To Consumer Advertising ◽  
Prescription Drug Market

The release of clarified Food and Drug Administration (FDA) guidelines and independent changes in consumer behavior provide an opportunity to study the effects of direct-to-consumer advertising (DTCA) in the prescription drug market alongside the effects of various physician-oriented promotions. We examine the effects of DTCA and detailing for brands in five therapeutic classes of drugs, using monthly aggregate U.S. data from August 1996 through December 1999. In terms of impact of DTCA on demand, we provide evidence on two issues: (1) do increases in DTCA increase the market size of an entire therapeutic class? and (2) does DTCA increase within-class market share of advertised drugs? Our findings suggest that, for these classes of drugs, DTCA has been effective primarily through increasing the size of the entire class. Overall, we estimate that 13 to 22 percent of the recent growth in prescription drug spending is attributable to the effects of DTCA.

Vraag uw huisarts om meer informatie

2010 ◽  
Vol 38 (1) ◽  
Author(s):  
Sandra Zwier ◽  
André Boekhorst
Keyword(s):  
Prescription Drug ◽  
European Commission ◽  
Empirical Evidence ◽  
Prescription Drugs ◽  
Public Debate ◽  
Drug Advertising ◽  
European Context ◽  
Direct To Consumer ◽  
Prescription Drug Advertising ◽  
Direct To Consumer Advertising

Ask your doctor: From prescription drug advertising to physician’s prescription Ask your doctor: From prescription drug advertising to physician’s prescription Ongoing proposals by the European Commission to adapt the current ban on direct-to-consumer advertising of prescription drugs (DTCA) are generating much public debate. This article reviews the –mainly US based– empirical evidence for the effects of DTCA on a) consumers’ exposure, b) consumers’ requests for advertised drugs, and c) physicians’ reactions to these requests, and discusses how the Dutch and broader European context can impact upon these effects. It is concluded that there is empirical evidence for DTCA’s impact on American consumers and physicians, but also that the European context is likely to reduce the strength of these effects.

Sign in / Sign up

Export Citation Format

Share Document